文献速递乳腺癌

循环嗜酸性粒细胞与激素受体阳性/HER2阴性乳腺癌全身免疫激活及复发减少的关联

Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
PubMed 文献 · J Clin Oncol · 2026-10-20

该研究在发现队列(N=472)中评估术前嗜酸性粒细胞计数与激素受体阳性/HER2阴性乳腺癌预后的关联,并在独立扩展队列(N=23,170)中采用倾向评分重叠加权验证。结果显示较高嗜酸性粒细胞计数与显著改善的无复发生存和远处无转移生存相关,且提供超越21基因复发评分的附加预后价值,并可预测高危患者从CDK4/6抑制剂辅助治疗中的获益。

要点

  • 术前循环嗜酸性粒细胞计数较高与激素受体阳性/HER2阴性乳腺癌复发风险降低独立相关。
  • 嗜酸性粒细胞计数提供超越21基因复发评分的附加预后价值。
  • 在高危患者中,嗜酸性粒细胞水平可预测CDK4/6抑制剂辅助治疗的获益亚组。

核心结论

  • 循环嗜酸性粒细胞计数可作为临床适用的液体活检生物标志物,独立预测激素受体阳性/HER2阴性乳腺癌的复发风险并预测CDK4/6抑制剂获益,反映全身免疫激活。

研究设计与样本

  • 多模态发现队列(N=472)评估术前嗜酸性粒细胞计数与患者结局的关联。
  • 独立扩展队列(N=23,170)通过多变量和倾向评分重叠加权分析进行验证。
  • 在具有21基因复发评分的患者(n=2,973)中评估嗜酸性粒细胞的附加价值,并在高危患者(n=3,471)中评估其对辅助CDK4/6抑制剂获益的预测作用。
  • 机制研究采用整合多组学、空间数字病理学和体内临床前模型。

主要发现

  • 在发现队列中,较高的循环嗜酸性粒细胞计数与显著改善的无复发生存和远处无转移生存相关。
  • 基因组分析显示嗜酸性粒细胞计数升高与较低的人类白细胞抗原纯合性及增加的瘤内免疫激活相关。
  • 嗜酸性粒细胞与抗肿瘤效应相关,并有CD8+ T细胞参与的 evidence。
  • 在EMT6(BALB/c)和E0771(C57BL/6)小鼠模型中,嗜酸性粒细胞过继转移显著减轻肿瘤负荷。
  • 空间分析显示肿瘤浸润嗜酸性粒细胞主要与淋巴细胞共聚集。

关键数值与推荐

  • 嗜酸性粒细胞水平在21基因复发评分之外提供附加预后价值。
  • 在高危患者中,嗜酸性粒细胞水平预测从CDK4/6抑制剂治疗中获益更大的亚组。

临床怎么用

  • 循环嗜酸性粒细胞计数或可作为激素受体阳性/HER2阴性乳腺癌复发风险的简便、非侵入性生物标志物。
  • 该指标可能辅助识别从辅助CDK4/6抑制剂治疗中获益更大的高危患者亚组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the most common subtype, lacks simple, noninvasive biomarkers for recurrence. We evaluated circulating eosinophil count as a clinically applicable biomarker for recurrence in this population. METHODS: Associations between preoperative eosinophil count and patient outcomes were evaluated in a multimodal discovery cohort (N = 472) and validated via propensity score overlap weighting in an independent expanded cohort (N = 23,170). We assessed the additive value of eosinophils in patients with 21-gene recurrence scores (RSs; n = 2,973) and their predictive role for adjuvant cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in high-risk patients (n = 3,471). Mechanisms were investigated using integrated multiomics, spatial digital pathology, and in vivo preclinical models. RESULTS: Higher circulating eosinophil counts correlated with significantly improved recurrence-free and distant metastasis-free survival in the discovery cohort. Genomic analysis associated these elevated counts with lower human leukocyte antigen homozygosity and increased intratumoral immune activation. Functionally, eosinophils were associated with antitumor effects, with evidence of CD8+ T-cell involvement. These findings were further validated in vivo, where eosinophil adoptive transfer significantly reduced tumor burden in both the EMT6 (BALB/c) and E0771 (C57BL/6) mouse models. Spatial profiling demonstrated that tumor-infiltrating eosinophils predominantly coaggregated with lymphocytes. These clinical associations were then validated in the independent expanded cohort through multivariable and propensity score-weighted analyses. Critically, eosinophil levels provided additive prognostic value beyond the 21-gene RS and, among high-risk patients, predicted the subset that would derive greater benefit from CDK4/6 inhibition. CONCLUSION: Circulating eosinophil count serves as a potential clinically applicable, liquid biopsy biomarker that independently prognosticates recurrence risk and predicts CDK4/6 inhibitor benefit, reflecting systemic immune activation in hormone receptor-positive/HER2- breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Li ZQ, Wu SY, Ge LP, et al. Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. J Clin Oncol. 2026. PMID: 42900864. doi:10.1200/JCO-26-00261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。